Federated Hermes Inc. Sells 2,172 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Key Points

• Federated Hermes Inc. sold 2,172 shares of Charles River Laboratories International, reducing its holdings by 90.6% to only 225 shares, leaving their investment valued at approximately $34,000.
• Several institutional investors have significantly increased their stakes in Charles River Laboratories International, with some boosts reaching over 16,000%, resulting in 98.91% of the company's stock now being held by institutional investors.
• Charles River Laboratories recently achieved $3.12 EPS for the quarter, surpassing analyst expectations and reporting revenue of $1.03 billion, showing a revenue increase of 0.6% compared to the same quarter last year.

Federated Hermes Inc. trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 90.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225 shares of the medical research company's stock after selling 2,172 shares during the quarter. Federated Hermes Inc.'s holdings in Charles River Laboratories International were worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. D1 Capital Partners L.P. purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $172,752,000. Assenagon Asset Management S.A. boosted its holdings in shares of Charles River Laboratories International by 1,721.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock valued at $85,811,000 after acquiring an additional 538,792 shares during the last quarter. Nomura Holdings Inc. purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $56,820,000. SG Americas Securities LLC boosted its holdings in shares of Charles River Laboratories International by 16,153.2% during the 1st quarter. SG Americas Securities LLC now owns 267,202 shares of the medical research company's stock valued at $40,219,000 after acquiring an additional 265,558 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $42,776,000. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CRL. Wall Street Zen raised shares of Charles River Laboratories International from a "hold" rating to a "strong-buy" rating in a report on Saturday. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Robert W. Baird raised their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. Finally, Barclays raised their price objective on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a report on Thursday, August 7th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus price target of $175.69.

Insider Buying and Selling

In other news, EVP Joseph W. Laplume sold 400 shares of the business's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $150.04, for a total transaction of $60,016.00. Following the completion of the sale, the executive vice president directly owned 24,916 shares of the company's stock, valued at approximately $3,738,396.64. The trade was a 1.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Up 0.0%

NYSE CRL opened at $148.75 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The company has a fifty day moving average of $155.83 and a two-hundred day moving average of $149.00. The firm has a market capitalization of $7.32 billion, a price-to-earnings ratio of -111.84, a PEG ratio of 4.74 and a beta of 1.48. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. Charles River Laboratories International's quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.80 earnings per share. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.